<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684515</url>
  </required_header>
  <id_info>
    <org_study_id>P05005</org_study_id>
    <nct_id>NCT00684515</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)</brief_title>
  <official_title>Phase II Study of SCH 530348 in Subjects With Cerebral Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin)
      in Japanese subjects with cerebral infarction. The study will assess incidence and
      tolerability of bleeding, major adverse cardiac events, all adverse events, and effect on
      expression of markers of inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2006</start_date>
  <completion_date type="Actual">November 8, 2007</completion_date>
  <primary_completion_date type="Actual">November 8, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE)</measure>
    <time_frame>Up to Day 121</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Paticipants Experiencing Thrombolysis in Myocardial Infarction (TIMI) Major, Minor, and Non-TIMI Bleeding Events</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Major TIMI bleeding was defined as any intracranial bleeding (excluding micohemorrhages &lt;10 mm evident on magnetic resonance imaging [MRI]), clinical over signs of hemorrhge associated with a drop in hemoglobin &gt;=5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in a hemoglobin drop of 3 to &lt;5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI or Minor TIMI bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MACE or Death</measure>
    <time_frame>Up to Day 121</time_frame>
    <description>The number of participants experiencing major cardiac events or death was evaluated up to Day 121. Major cardiac events were defined as nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels By Study Visit</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Participant blood samples were collected to determine the median serum level of hs-CRP. hs-cRP levels reflect the underlying level of inflammation. The higher the level, the greater the disease burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CD40 Ligand Levels By Study Visit</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Participant blood samples were collected to determine the mean serum level of CD40 ligand. CD40 ligand values represent the level of disease activation with a higher level of CD40 ligand indicating a greater underlying risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Membrane-Bound P-Selectin Levels By Study Visit</measure>
    <time_frame>Up to Day 60</time_frame>
    <description>Participant blood samples were collected at Baseline, Day 30, and Day 60 to determine the mean level of membrane-bound p-selectin in the serum. Membrane-bound P-selectin levels reflect the underlying level of inflammation. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Vorapaxar 2.5 mg + Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorapaxar oral tablets; once daily for 60 days + Aspirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vorapaxar 1 mg + Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorapaxar oral tablets; once daily for 60 days + Aspirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Aspirin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets; once daily for 60 days + Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar 2.5 mg</intervention_name>
    <description>Oral tablets; once daily for 60 days.</description>
    <arm_group_label>Vorapaxar 2.5 mg + Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar 1 mg</intervention_name>
    <description>Oral tablets; once daily for 60 days</description>
    <arm_group_label>Vorapaxar 1 mg + Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets; once daily for 60 days</description>
    <arm_group_label>Placebo + Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 75-150 mg</intervention_name>
    <description>oral tablets; once daily for 60 days</description>
    <arm_group_label>Vorapaxar 2.5 mg + Aspirin</arm_group_label>
    <arm_group_label>Vorapaxar 1 mg + Aspirin</arm_group_label>
    <arm_group_label>Placebo + Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women at least 18 years old with last cerebral infarction (excluding
             cardiogenic cerebral embolism) having occurred from 14 days to less than 1 year after
             onset (at the time of obtaining consent), with stable nervous system for more than 24
             hours and known course of disease.

          -  Participants confirmed to have cerebral infarction lesion by brain computerized
             tomography (CT) or magnetic resonance imaging (MRI).

          -  Both of in-participant and out-participant

          -  Willing to give appropriate informed consent and complete all study-related procedures
             and able to adhere to dosing and visit schedules.

          -  Women of child-bearing potential (all postmenopausal women who are &lt;1 year menopausal
             or who have not had surgical sterilization or a hysterectomy are considered to be
             women of child-bearing potential) must agree to use a medically accepted method of
             contraception while receiving protocol-specified study drug, and for 60 days after
             completion or discontinuation of the medication.

        Exclusion Criteria:

          -  Pregnancy and nursing patients (premenopausal women should have a negative pregnancy
             test result confirmed before enrollment)

          -  Participant with any serious complication or any condition that the investigator feels
             that would cause a significant hazard to the participant if the study drug is
             administered.

          -  Known hypersensitivity to any component of the study drug.

          -  Participation in a study or use of an investigational study drug within 30 days before
             obtaining consent.

          -  Member of the staff personnel directly involved with this study

          -  Family member of the study staff.

          -  History of a bleeding diathesis, or evidence of active abnormal bleeding within 30
             days before obtaining consent.

          -  History of cerebral hemorrhage.

          -  Severe hypertension (systolic blood pressure &gt;200 mmHg or diastolic blood pressure
             &gt;110 mmHg).

          -  Major surgery within 2 weeks before obtaining consent.

          -  Known platelet count &lt;100,000/mm^3

          -  Participants confirmed to have cerebral bleeding or any causes of cerebral bleeding by
             brain CT or MRI.

          -  Participants with transient ischemic attack (TIA), progressive stroke or cardiogenic
             cerebral embolism.

          -  Known impairment of renal function (serum creatinine &gt;2.0 mg/dL [&gt;176.8 (umol/L]),
             dysproteinemia, nephrotic syndrome, or other renal disease

          -  Active or chronic hepatobiliary system or hepatic disease, or aspartate
             aminotransferase (GOT) or alanine aminotransferate (GPT) activity more than two times
             greater than the upper limit of the laboratory normal range.

          -  Participants with contraindictation to aspirin.

          -  Scheduled to have PCI (peripheral coronary intervention), peripheral interventional
             event, carotid endarterectomy, intra- and extra- cranial bypass surgery and
             intravascular surgery (angioplasty) during the study period.

          -  Combination therapy with unfractionated heparin, tissue plasminogen activator,
             urokinase, warfarin, factor Xa inhibitor, direct thrombin inhibitor or antiplatelet
             agents other than aspirin after obtaining consent, or scheduled to have the above
             combination therapy.

          -  Any serious impairment which would make detection of new ischemic events difficult
             (eg, bedridden participants, participants with total nursing care, dementia
             participants, etc.) or consciousness disturbance which may cause aspiration of the
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Shinohara Y, Goto S, Doi M, Jensen P. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis. 2012 May;21(4):318-24. doi: 10.1016/j.jstrokecerebrovasdis.2010.09.005. Epub 2010 Oct 14.</citation>
    <PMID>20947374</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>July 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2014</results_first_posted>
  <disposition_first_submitted>October 9, 2008</disposition_first_submitted>
  <disposition_first_submitted_qc>October 21, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 22, 2009</disposition_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P05005&amp;kw=P05005&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vorapaxar 1 mg</title>
          <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="P2">
          <title>Vorapaxar 2.5 mg</title>
          <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-Defined Clinical Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vorapaxar 1 mg</title>
          <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="B2">
          <title>Vorapaxar 2.5 mg</title>
          <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="10.0"/>
                    <measurement group_id="B2" value="65.8" spread="11.6"/>
                    <measurement group_id="B3" value="63.7" spread="8.9"/>
                    <measurement group_id="B4" value="64.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE)</title>
        <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.</description>
        <time_frame>Up to Day 121</time_frame>
        <population>The population consisted of all enrolled participants that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Non-Major Adverse Cardiac Events (Non-MACE)</title>
          <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.</description>
          <population>The population consisted of all enrolled participants that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Paticipants Experiencing Thrombolysis in Myocardial Infarction (TIMI) Major, Minor, and Non-TIMI Bleeding Events</title>
        <description>Major TIMI bleeding was defined as any intracranial bleeding (excluding micohemorrhages &lt;10 mm evident on magnetic resonance imaging [MRI]), clinical over signs of hemorrhge associated with a drop in hemoglobin &gt;=5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in a hemoglobin drop of 3 to &lt;5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI or Minor TIMI bleeding.</description>
        <time_frame>Up to Day 60</time_frame>
        <population>The population consisted of all enrolled participants that received at least one dose of study drug and had TIMI bleeding data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Paticipants Experiencing Thrombolysis in Myocardial Infarction (TIMI) Major, Minor, and Non-TIMI Bleeding Events</title>
          <description>Major TIMI bleeding was defined as any intracranial bleeding (excluding micohemorrhages &lt;10 mm evident on magnetic resonance imaging [MRI]), clinical over signs of hemorrhge associated with a drop in hemoglobin &gt;=5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in a hemoglobin drop of 3 to &lt;5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI or Minor TIMI bleeding.</description>
          <population>The population consisted of all enrolled participants that received at least one dose of study drug and had TIMI bleeding data available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major TIMI Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor TIMI Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-TIMI Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MACE or Death</title>
        <description>The number of participants experiencing major cardiac events or death was evaluated up to Day 121. Major cardiac events were defined as nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization.</description>
        <time_frame>Up to Day 121</time_frame>
        <population>The population consisted of all enrolled participants that received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MACE or Death</title>
          <description>The number of participants experiencing major cardiac events or death was evaluated up to Day 121. Major cardiac events were defined as nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization.</description>
          <population>The population consisted of all enrolled participants that received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels By Study Visit</title>
        <description>Participant blood samples were collected to determine the median serum level of hs-CRP. hs-cRP levels reflect the underlying level of inflammation. The higher the level, the greater the disease burden.</description>
        <time_frame>Up to Day 60</time_frame>
        <population>The population consisted of all enrolled participants who received at least one dose of study drug and had hs-CRP data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels By Study Visit</title>
          <description>Participant blood samples were collected to determine the median serum level of hs-CRP. hs-cRP levels reflect the underlying level of inflammation. The higher the level, the greater the disease burden.</description>
          <population>The population consisted of all enrolled participants who received at least one dose of study drug and had hs-CRP data available.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=33, 29, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.44"/>
                    <measurement group_id="O2" value="0.67" spread="1.66"/>
                    <measurement group_id="O3" value="0.56" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=32, 28, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="2.33"/>
                    <measurement group_id="O2" value="0.49" spread="0.73"/>
                    <measurement group_id="O3" value="0.41" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (32, 29, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="2.69"/>
                    <measurement group_id="O2" value="0.62" spread="0.79"/>
                    <measurement group_id="O3" value="0.44" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=31, 28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="3.95"/>
                    <measurement group_id="O2" value="0.55" spread="1.07"/>
                    <measurement group_id="O3" value="0.56" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 45 (n=29, 27, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="1.09"/>
                    <measurement group_id="O2" value="0.48" spread="0.74"/>
                    <measurement group_id="O3" value="0.59" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 (n=29, 26, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.58"/>
                    <measurement group_id="O2" value="0.53" spread="0.63"/>
                    <measurement group_id="O3" value="0.61" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean CD40 Ligand Levels By Study Visit</title>
        <description>Participant blood samples were collected to determine the mean serum level of CD40 ligand. CD40 ligand values represent the level of disease activation with a higher level of CD40 ligand indicating a greater underlying risk.</description>
        <time_frame>Up to Day 60</time_frame>
        <population>The population consisted of all enrolled participants that received at least one dose of study drug and had CD40 ligand data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean CD40 Ligand Levels By Study Visit</title>
          <description>Participant blood samples were collected to determine the mean serum level of CD40 ligand. CD40 ligand values represent the level of disease activation with a higher level of CD40 ligand indicating a greater underlying risk.</description>
          <population>The population consisted of all enrolled participants that received at least one dose of study drug and had CD40 ligand data available.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=33, 29, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.62"/>
                    <measurement group_id="O2" value="8.3" spread="0.77"/>
                    <measurement group_id="O3" value="5.9" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=32, 28, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="0.71"/>
                    <measurement group_id="O2" value="5.8" spread="0.74"/>
                    <measurement group_id="O3" value="5.6" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=32, 29, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.64"/>
                    <measurement group_id="O2" value="6.5" spread="0.79"/>
                    <measurement group_id="O3" value="6.6" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=31, 28, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.79"/>
                    <measurement group_id="O2" value="7.1" spread="0.78"/>
                    <measurement group_id="O3" value="5.9" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 45 (n=29, 27, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="0.77"/>
                    <measurement group_id="O2" value="5.7" spread="0.77"/>
                    <measurement group_id="O3" value="6.2" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 (n=29, 26, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.82"/>
                    <measurement group_id="O2" value="5.3" spread="0.76"/>
                    <measurement group_id="O3" value="6.0" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Membrane-Bound P-Selectin Levels By Study Visit</title>
        <description>Participant blood samples were collected at Baseline, Day 30, and Day 60 to determine the mean level of membrane-bound p-selectin in the serum. Membrane-bound P-selectin levels reflect the underlying level of inflammation. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels.</description>
        <time_frame>Up to Day 60</time_frame>
        <population>The population consisted of all enrolled participants that received at least one dose of study drug and had membrane-bound p-selectin data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorapaxar 1 mg</title>
            <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Vorapaxar 2.5 mg</title>
            <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Membrane-Bound P-Selectin Levels By Study Visit</title>
          <description>Participant blood samples were collected at Baseline, Day 30, and Day 60 to determine the mean level of membrane-bound p-selectin in the serum. Membrane-bound P-selectin levels reflect the underlying level of inflammation. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels.</description>
          <population>The population consisted of all enrolled participants that received at least one dose of study drug and had membrane-bound p-selectin data available.</population>
          <units>Arbitrary Units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="0.80"/>
                    <measurement group_id="O2" value="19.5">Due to the sample size of 1 participant, calculation of the SE was not possible.</measurement>
                    <measurement group_id="O3" value="17.4" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 (n=2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="4.20"/>
                    <measurement group_id="O2" value="16.6">Due to the sample size of 1 participant, calculation of the SE was not possible.</measurement>
                    <measurement group_id="O3" value="17.1" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60 (n=2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="0.05"/>
                    <measurement group_id="O2" value="18.3">Due to the sample size of 1 participant, calculation of the SE was not possible.</measurement>
                    <measurement group_id="O3" value="18.0" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 121</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vorapaxar 1 mg</title>
          <description>Vorapaxar 1 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="E2">
          <title>Vorapaxar 2.5 mg</title>
          <description>Vorapaxar 2.5 mg tablets administered orally once daily for 60 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching placbo tablets to Vorapaxar administered orally once daily for 60 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Diathesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood Potassium Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Blood Urine Present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT Prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Occult Blood Positive</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Haemorrhage Subcutaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior approval by the Sponsor is required before the results obtained in the clinical study can be made public by the investigator (sub-investigator) in a publication or at a medical meeting.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

